Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved axatilimab-csfr (Niktimvo, Incyte Corporation) for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing 40 kg or more. Axatilimab-csfr is a colony-stimulating factor-1 receptor-blocking antibody.
Efficacy was evaluated in AGAVE-201 (ClinicalTrials.gov. Identifier: